<DOC>
	<DOCNO>NCT02814617</DOCNO>
	<brief_summary>The investigator perform randomize , double-blind , placebo-controlled human trial evaluate efficacy safety Cordyceps sinensis mycelium culture extract ( Paecilomyces hepiali , CBG-CS-2 ) promotion immunity . The investigator measure promotion immunity parameter , include Cytotoxicity , Cytokine ( IL-1β , IL-2 , IL-4 , IL-10 , IL-12 , IFN-γ , TNF-α ) .</brief_summary>
	<brief_title>The Efficacy Safety Cordyceps Sinensis Mycelium Culture Extract ( Paecilomyces Hepiali , CBG-CS-2 ) Promotion Immunity</brief_title>
	<detailed_description />
	<criteria>Males female 2075 year old Able give inform consent WBC concentration 3000 ㎕ , 8000㎕ Subjects BMI ＜ 18.5 kg/m2 screen visit Allergic hypersensitive ingredient test product Diagnosed gastrointestinal disease Immunerelated diseases , severe hepatic , renal failure , diabetes History reaction test product gastrointestinal disease Crohn 's disease gastrointestinal surgery History alcohol substance abuse Participation clinical trial within past 2 month Laboratory test , medical psychological condition deem investigator interfere successful participation study Pregnant lactate woman etc .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>